The 50% normal-tissue complication probability (NTCP) after lobar irradiation of the liver results in highly variable biologic effective doses depending on the modality used: a biologic effective dose for 50% (BED 50 ) of 115, 93, and 250 Gy for external-beam radiotherapy, resin microsphere radioembolization, and glass microsphere radioembolization, respectively. This misunderstood property has made it difficult to predict the maximal tolerable dose as a function of microsphere activity and targeted liver volume. The evolution toward more selective catheterization techniques, resulting in more variable targeted volumes, makes it urgent to solve this issue. Methods: We computed by Monte Carlo simulations the microsphere distribution in the portal triads based on microsphere transport dynamics through a synthetically grown hepatic arterial tree. Afterward, the microscale dose distribution was computed using a dose deposition kernel. We showed that the equivalent uniform dose cannot handle microscale dosimetry and fails to solve the discordance between the BED 50 values. Consequently, we developed a new radiobiologic model to compute the liver NTCP from the microscale dose distribution. Results: The new model explains all the observed BED 50 values and provides a way to compute the hepatic dose-toxicity relationship as a function of microsphere activity and targeted liver volume. The NTCP obtained is in agreement with the data reported from clinical radioembolization studies.
Conclusion:The results should encourage interventional radiologists to fine-tune the delivered dose to the liver as a function of the targeted volume. The present model could be used as the backbone of the treatment planning, allowing optimization of the absorbed dose to the tumors. Sel ective internal radiation therapy by radioembolization with 90 Y-loaded microspheres is becoming a common procedure in patients with primary hepatic neoplasia and liver-dominant metastatic disease. The evolution toward more selective catheterization techniques makes it urgent to use a model predicting the maximal tolerable delivered dose as a function of the radioembolization device and the targeted liver volume.Recommendations for lobar radioembolization of the liver differ in maximal tolerable absorbed dose according to the medical device: less than 70 Gy when using 50 Bq of loaded resin microspheres (1) and less than 120 Gy when using 2,500 Bq of loaded glass microspheres (2). Recent voxel-based dosimetry SPECT/CT studies (3,4) support a similar difference in hepatic toxicity risk per gray for these 2 therapies. For hepatocarcinoma treated with resin spheres, Strigari et al. (3) The biologic effective dose (BED) formalism accounts for the difference in dose rates between irradiation modalities (3,6). However, the resulting biologic effective dose for 50% (BED 50 ) is still highly discordant: 115, 93, and 250 Gy for EBRT, resin microsphere radioembolization, and glass microsphere radioembolization, respectively. The values used to compute BED (a/b 5 2.5 Gy a...